Needham analyst Gil Blum downgraded Sarepta (SRPT) to Hold from Buy.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- Sarepta CEO says didn’t disclose patient death on Weds. call, ‘wasn’t salient’
- Another liver toxicity death adds to Sarepta concerns, says Morgan Stanley
- Sarepta price target lowered to $20 from $28 at BofA
- Sarepta not disclosing death ‘deeply troubling,’ says Leerink
- Sarepta knew of patient death when announcing restructuring , Stat says